Cadrenal Therapeutics, Inc. (CVKD)
(Delayed Data from NSDQ)
$0.41 USD
-0.01 (-2.36%)
Updated Aug 7, 2024 03:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
CVKD 0.41 -0.01(-2.36%)
Will CVKD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CVKD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CVKD
IPO Round Up of First Half of 2023
CVKD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CVKD
CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024
Abbott to collaborate with Cadrenal on anticoagulant tecarfarin
Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs
Cadrenal Therapeutics Partners with Abbott on Cardiac Trial
Cadrenal Therapeutics and Abbott partner to develop anticoagulant tecarfarin